Gillian Woollett | Vice President
Samsung Bioepis

Gillian Woollett, Vice President, Samsung Bioepis

Dr. Gillian Woollett joined Samsung Bioepis in November 2021 as VP, Head Regulatory Strategy and Policy, US (SBUS), to stand up a US presence for science-based regulatory strategy and policy in the leading global market for biologics, including but not limited to biosimilars.

Prior to this recent move, she was SVP and Principal Regulatory Scientist at Avalere Health where she created and led the FDA Policy and Regulatory Strategy Practice. Avalere, an advisory services firm of ~250 people, supported clients across the healthcare spectrum, from patients to biopharma companies and payers/providers. She provided the “prequel” of scientific and technical expertise to support drugs, biologics and devices gaining approval at the FDA in a manner that allows them to be commercially successful. She led on peer reviewed publications supporting regulatory reliance globally, including harmonization (US)/ convergence (EU) to facilitate access and affordability. She created the Avalere FDA Fellows Program to enable scientists to transition effectively into the policy environment with >40 having used this steppingstone to transition their careers.
 
Dr. Woollett has represented the biopharma industry in the media as the industries’ voice on international, as well as US, regulatory and scientific issues.  She has been appointed to Federal Advisory Committees; for example, she represented industry on CDC’s Board of Scientific Counsellors to the National Center for Infectious Disease. She currently represents biotechnology on the Material and Engineering Technical Advisory Committee (METAC) at the Department of Commerce and chairs the Biotech Work Group. She also provides a point of scientific interface with academic and professional organizations. She is an appointee to the Nomenclature and Labeling Expert Committee of the United States Pharmacopeia (USP),  was on the Board for the Foundation for The Accreditation of Cellular Therapy (FACT) for almost a decade, and served on the Science Board of the Pharmaceutical Education Research Institute (PERI). 
 
Dr. Woollett earned her B.A., M.A. in Biochemistry from the University of Cambridge, and her D.Phil. in
Immunology from the University of Oxford in the UK. She was a post-doc in the Department of Molecular Biology at the University of Edinburgh, and at the Biomedical Research Institute, Rockville, MD funded by USAID. She is well published in the peer reviewed literature.

Appearances:



Festival of Biologics Day 1 @ 10:00

Opening Keynote Panel: What will shape the future of biosimilars, from a regulatory perspective?

Festival of Biologics Day 1 @ 17:30

Panel Discussion: The Value of Interchangeability

Festival of Biologics Day 2 @ 09:30

Is it time for global biosimilar development?

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers